{"id":"NCT00293059","sponsor":"Bayer","briefTitle":"Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","officialTitle":"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-02-17","resultsPosted":"2011-06-06","lastUpdate":"2013-11-27"},"enrollment":190,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metrorrhagia"],"interventions":[{"type":"DRUG","name":"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.","primaryOutcome":{"measure":"Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms","timeFrame":"during a time period of 90 days under treatment","effectByArm":[{"arm":"Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027)","deltaMin":0.292,"sd":null},{"arm":"Placebo","deltaMin":0.029,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":46,"countries":["United States","Canada"]},"refs":{"pmids":["22240178","21422847","21774563"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":119},"commonTop":["Headache","Nasopharyngitis","Nausea","Vaginitis bacterial","Weight increased"]}}